ENTX
NASDAQEntera Bio
$1.33
+0.29 (+27.88%)
2026-02-09 00:00
Healthcare
Biotechnology
--
--
Market Cap
$61.0M
P/E Ratio
N/A
52W Low
52W High
$1.00
$3.22
Volume
528K
Analyst Rating
Hold
Target: $10
2 Analyst Ratings
Strong Buy
0
Buy
0
Hold
2
Sell
0
Price Target Range
Low: $10
Avg: $10
High: $10
About Entera Bio
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis; ...
Employees
20
Website
enterabio.com
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2024 | -5295.6% | |||
| 2023 | -63857.1% | |||
| 2022 | -9714.2% | |||
| 2021 | -2139.6% | |||
| 2020 | -3050.1% |